我們已在上線！進一步了解

Bristol-Myers Squibb

BMY

市值 US$1221億

59.75 USD

-0.82

1.35%

收盤時已更新 10月16日下午4:00 EDT

盤前交易

盤後交易

60.19

+0.44

0.74%

1天

-1.35%

5天

-0.6%

1個月

-6.05%

3個月

-1.26%

6個月

1.34%

今年迄今

11.77%

1年

37.7%

5年

4.94%

10年

21.1%

關於： Bristol Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Bristol derives close to 70% of total sales from the US, showing a higher dependence on the US market than most of its peer group.

員工： 32,500

醫療保健藥品製造商－一般

新聞

正面

中性

負面

市場情緒 3個月

正面 53.7%

中性 35.2%

負面 11.1%

The Motley Fool

Bristol-Myers Squibb vs. Johnson & Johnson: Which Healthcare Stock Is a Better Buy in 2026?

Bristol-Myers Squibb offers a deep focus on oncology and hematology with a favorable valuation. Johnson & Johnson provides a diversified mix of innovative medicine and a massive medical technology division.

Bristol-Myers Squibb vs. Johnson & Johnson: Which Healthcare Stock Is a Better Buy in 2026?

24/7 Wall Street

Bristol Myers Squibb's 4.2% Dividend Yield Comes With a Trade-Off Investors Should Know

Bristol Myers Squibb has raised its dividend for 17 straight years, but a looming patent cliff and $43 billion in debt put the pace of future increases on a collision course with the drugs Wall Street is betting everything on.

Bristol Myers Squibb's 4.2% Dividend Yield Comes With a Trade-Off Investors Should Know

24/7 Wall Street

These 4 Dividend Stocks Passed the 2020 Stress Test. Are They Buys in Now October?

Four companies kept raising their dividends even as the pandemic hammered their sectors in 2020, and they are still raising today. The question is whether their yields and valuations make them worth buying right now.

These 4 Dividend Stocks Passed the 2020 Stress Test. Are They Buys in Now October?

Zacks Investment Research

Bristol Myers Squibb Company (BMY) Is a Trending Stock: Facts to Know Before Betting on It

Recently, Zacks.com users have been paying close attention to Bristol Myers (BMY). This makes it worthwhile to examine what the stock has in store.

Bristol Myers Squibb Company (BMY) Is a Trending Stock: Facts to Know Before Betting on It

24/7 Wall Street

Blockbuster Drugs Come and Go. These 5 Pharma Dividend Stocks Keep Paying

Every big pharma company eventually watches its best-selling drug go generic, yet some keep raising their dividends anyway.

Blockbuster Drugs Come and Go. These 5 Pharma Dividend Stocks Keep Paying

The Motley Fool

Bristol Myers Squibb vs. Eli Lilly: Which Healthcare Stock Is a Better Buy in 2026?

Bristol Myers Squibb offers a significant yield and recovery in net income, supported by its strong oncology and cardiovascular segments. Eli Lilly & Co. is experiencing massive growth in revenue and profitability, driven by its leadership in the obesity and diabetes treatment markets.

Bristol Myers Squibb vs. Eli Lilly: Which Healthcare Stock Is a Better Buy in 2026?

Zacks Investment Research

BMY Reports Mixed Phase III Trial Results, Stock Down

Bristol Myers Squibb reports mixed Phase III results for admilparant in IPF, while RYZ101 delivers a significant win in advanced GEP-NETs.

BMY Reports Mixed Phase III Trial Results, Stock Down

Federal and state regulators asked a judge to hold “pharma bro” Martin Shkreli in contempt, alleging he traded drug stocks despite a lifetime ban from the pharmaceutical industry

Regulators allege the ex-drug executive held more than 60 pharmaceutical stocks despite a court order barring him from the industry.

Federal and state regulators asked a judge to hold “pharma bro” Martin Shkreli in contempt, alleging he traded drug stocks despite a lifetime ban from the pharmaceutical industry

Business Insider

FTC says Martin Shkreli 'flagrantly and repeatedly' violated his lifetime pharma ban

The Federal Trade Commission said Martin Shkreli is still trading pharmaceutical stocks. The FTC said the "Pharma Bro" continues to do this despite a lifetime ban.

FTC says Martin Shkreli 'flagrantly and repeatedly' violated his lifetime pharma ban

‘Pharma Bro' Martin Shkreli is in trouble with regulators again, this time for influencing biopharma stocks

The controversial investor has been weighing in on biopharma stocks even though he's banned from doing so.

‘Pharma Bro' Martin Shkreli is in trouble with regulators again, this time for influencing biopharma stocks

查看新聞排名

價格圖表採用Lightweight Charts™實作